Ruzivo rutsva pamusoro pehupenyu huri shure kwekurwiswa kwemigraine zvinoreva kurapa kwakanaka
Migraine chirwere chakakomba chepfungwa chinokanganisa kunyange masayendisiti akangwara uye maitiro emagetsi anowanzochera misoro yavo. Kusiyana nezvimwe zvirwere zvakawanda zvehutano, hupenyu hwemagraine kurwisa hauna kumboitika.
Nhau dzakanaka ndeyokuti vatsvakurudzi varikupedzisira vava kuswedera pedyo nokunzwisisa "sei" shure kwekurwiswa kwemagraine-kureva maitiro avo ekurapa, kana kuti maitiro avaratidza sei.
Ndiyo zivo iyo yakashandura migraine therapies, ichiisa chikwata chezvidzidzo zvinovimbiswa uye mishonga mitsva inobuda.
Ikoko hutatu hukuru hunobudirira mune migraine therapy inosanganisira:
- Nzira dzakasiyana-siyana dzokugadzirisa triptans, yakatova yakagadzirirwa anti-migraine drug.
- Novel anti-migraine mishonga yekurapa kwakanyanya uye kudzivirira.
- Zvirwere zvokurapa kubata uye kudzivirira migraines.
Triptans Inonunurwa Zvimwe
Triptans inosunga serotonin receptors muuropi uye inowanzoshandiswa kurapa kuenzanisa-kusvika-yakaoma migraine kurwisa. Iyo inoshandiswawo kubata mushonga-kusvika-kuenzanisa migraines asingasimbisi neNSAID .
Runako rwetatu hunofanirwa kubudiswa nenzira dzakawanda-mahwendefa, mahwendefa omumuromo anoputika (zvakaputika), nasal spray, subcutaneous injection (pasi peganda), uye pasi.
Nezvose izvi zvingasarudzwa, munhu ane migraines uye chiremba wake anogona kusarudza triptan, zvichienderana nezvinodiwa zvakasiyana nezvinodiwa.
Izvi zvinogona kusanganisira:
- Zvikanganiso
- Kutanga kwechiito
- Kuteterera kune vamwe vanhu vanoita migrauneurs-somuenzaniso, avo vanoona kushungurudzika uye kurutsa nemigraine yavo uye havagoni kushivirira mishonga nemuromo
- Mutengo
- Kunaka
Zvinonakidzawo kuziva kuti triptans inogona kugadziriswa nenzira dzakasiyana zvikuru mune ramangwana.
Semuenzaniso, sumatriptan lingual spray irikudziridzwa iye zvino, sezvinonzi macmitriptan inhaler uye rizatriptan muromo kupera bhafirimu.
Ramba uchiyeuka kuti itsva formulations haisi kubudirira nguva dzose. Semuenzaniso, sumatriptan yakashandiswa kuvapo sebheteri-inowanika transdermal patch (inonzi Zecuity) iyo yakashandiswa kuruoko rukuru kana gumbo. Yakapinda paganda uchishandiswa magetsi emagetsi, ichipa 6.5mg we sumatriptan kwemaawa mana. Zvisinei, ikozvino kubva pamusika nemhaka yemishumo yekutsva uye zviyo zvinosangana nazvo.
Mufananidzo mukuru pano ndewokuti mishonga mitsva uye maitiro anouya vimbiso, asiwo vamwe kushamiswa sezvo mavara anosvika kunze.
Yeuka zvakare, kuti kuumbwa kunoshanda kune munhu mumwe chete hakugone kushanda kune imwe-saka taura newachiremba wako kuti abudise zvinoshandiswa uye zvigadziriswa zvekugadzirisa mararamiro ako.
Novel Anti-Migraine Mishonga
Sezvo masayendisiti azarura biology mushure mekuti migraine kurwisa kunowedzera sei muuropi, vanogona kutsvaga nzira itsva uye zvinyorwa. Kufambira mberi zvitatu mumigraine zvinodhaka zvinosanganisira:
- Lasmiditan: Mishonga yakafanana kune dzimwe triptan asi nehukama hwakanyanya kune imwe serotonin receptor.
- Mishonga inobata Calcitonin Gene-Related Peptide (CGRP)
- Mishonga inobata Glutamate
Lasmiditan: A Serotonin 5-HT1F Agonist
Lasmiditan iri kukurudzirwa seimwe nzira yemishonga kune triptans . Sei imwe nzira inoda kudiwa? Pane zvikonzero zvitatu:
- Kutsvakurudza kunoratidza kuti vanenge 35 kubva muzana yevanhu havanzwisisi migraine kubva mumuromo we triptans.
- Nhamba yakanaka yevanhu haigoni kutora triptan nokuti inogona kukonzera ropa mhepo yakasimba (vasoconstriction) -so, triptans inopesana neavo vane nhoroondo yehutano hwemwoyo, kurwara, piripheral vascular disease , kusatariswa kwehuwandu hweropa, uye / kana zvimwe migraine se hemiplegic kana basilar migraine.
- Vamwe vanhu havanzwisisi kuti ma triptan anoita sei kuti vanzwe, sezvo vanogona kukonzera kusagadzikana nemigumisiro sejaya, mutsipa, uye chifuko chisimbiso, kupera, uye kurira (kunyanya kwechiso).
Nhau dzinopikira pamusoro pesmiditan ndeyokuti inosungirirana kune dzimwe nzvimbo dzinogamuchira serotonin muuropi, dzine hukama hwakawanda hwevamwe serotonin receptors iyo kana yakasungwa, inogona kutungamirira vasoconstriction isingadiwi.
Mashoko akanaka ndeokuti muchikamu chechipiri chechipiri, chirwere chinotorwa pamitambo yakasiyana-siyana chakawanikwa kuti chinatsiridza marwadzo kubva kune anononoka kusvika kune akaoma migraine musoro kune chero (kana kuti munyoro) mumaawa maviri. Kuvandudzwa kwekutambudzika kwaive kwakanyanya-kunomirira, kureva kukwirira kworuzha, kunyanya kunetseka kunorwadza.
Iyo huru migumisiro yechirwere yakange iri dutu (inowanikwa 38 muzana yevatori vechikamu) yakatevedzwa ne vertigo uye kuneta.
Nokudaro, kusiyana neamatoo matatu, iyo yakasungirirwa yakasimba inogona kuvhara vasoconstrictive madhara, asi inogona kutungamirira kune humwe hutano hwemagadzirirwo hunoita, izvo zvingave zvisingakwanisi kune vamwe vanhu. Kakawanda, zvidzidzo zvikuru uye mifananidzo yakajeka yegadziriro yemasimiditan inodiwa.
Calcitonin Gene-Related Peptide (CGRP)
Calcitonin peptide inokonzerwa nejeni (CGRP) inoita basa rinokosha mumigraine pathogenesis. Kunyanya zvakanyanya, kutsvakurudza kunoratidza kuti panguva yekurwiswa kwemagraine, urongwa hwetatu hunoitwa, hunoita kuti kusunungurwa kweCGRP kubva kune hutatu hwemagetsi hugumira. CGRP inoshandisa kuwedzera mishonga yeropa yakapoteredza uropi uye inotanga chiitiko chinonzi neurogenic kuvhiringidza, uye ndiwo matanho maviri aya anobva aita misoro yemucraine.
Saka, mishonga inogona kudzivirira CGRP pachayo kana kuti receptors (nzvimbo yekuchengetedza iri muuropi) yeCGRP iri kuongororwa. Zvinosuruvarisa, zvimwe zvidzidzo kuongorora CGRP-receptor vanopikisa (mishonga inodzivisa chiito cheCGRP) yakambomira kare kwechikonzero chezvikonzero, kusanganisira kunetseka pamusoro pechiropa chekutyisa. Asi imwe mishonga, inobatsira, yakabvumirwa zvakanaka uye inoshanda muchikamu chechipiri chechidzidzo.
Zvirwere zvitatu zvinopesana neCGRP zvinoshandiswa (zvinodhaka zvinosungira puroteni CGRP uye zvinodzivisa kana zvisingabatsiri) zvakagadzirirwawo kudzivirira migraines, nechinangwa chokubvisa kuwedzera kweCGRP yakabudiswa neutatu hwemagariro kuguma panguva yekurwiswa kwemigraine. Iyi mishonga inoratidza migumisiro yakavimbisa mukutanga kwekutanga 1 uye 2 miedzo.
Pakupedzisira, erenumab inonzi monoclonal antibody inosunga kwete kuCGRP, asi kune iyo inogamuchira, uye inopiwa pasi peganda (a subcutaneous injection). Nokusunga kumubati, erenumab inoidzivisa kubva pakuisa chiratidzo. Yakadzidziswa sechirwere chekudzivirira mishonga uye inoratidzika zvakanaka-inoregererwa muchikamu chechipiri chekudzidza.
Pasi pose, kutarisa nzira dzeCGRP kunoratidzika kuva chivimbiso chekurapa kune avo vane episodic kana asingagumi migraine disorder.
Glutamate Receptor Antagonists
Glutamate inonzi neurotransmitter, kana chikemikari muuropi, iyo maererano nemhuka dzose uye zvidzidzo zvevanhu, inoita seinoita basa rinokosha mukuita kunoita migraines. Mishonga yakawanda yakabatana nekuvhara kana kuchinja zvinogadziriswa zve glutamate zvakadzidzwa, zvimwe zvekurapa zvirwere zvakanyanya zvekudzivirira uye vamwe kudzivirira migraines.
Iwe unogona kunge uchitora kana kuti unoziva mishonga inodzivirira se-topamax (topiramate) uye botulinum chekisi A iyo inodzivirira glutamate kubudiswa, pamwe chete nemamwe makemikari.
Zvinofadza, ketamine (anesthetic drug), iyo inovhara mukana we glutamate muuropi inonzi iyo NMDA receptor, yakawanikwa kuti inobata migraine aura- zvichida nekudzivisa kuratidzira kupararira kuora mwoyo, kuwedzerwa kwepfungwa inoshungurudzika inoshungurudza nechepamusoro pekodhikisi ye uropi.
Muchikamu chiduku, chidzidzo chepachiviri-mapofu chevanhu vane nguva yakareba migraine aura, 25mg ye intranasal ketamine (yakapiwa kuburikidza nemhino) yakafananidzwa neinterranasal (midazolam) inozivikanwa, iyo inonzi sedative. Chidzidzo chacho chakawana kuti ketamine yakaderedza kusimba asi kwete nguva yeAra. Zvikanganiso zvinosanganisira:
- Manzwiro echokwadi
- Euphoria
- Temporary mild giddiness
Izvi zvinogumira pasi mukati memaminitsi makumi matatu kusvika ku45. Pasi pose, basa re glutamate uye nzira dzaro dzisingagumi migraine uye migraine aura rinoramba richiva chikonzero chekutsvakurudza, uye neizvozvo, tariro yezvinodiwa zvitsva.
Revolutionary FDA-Approved Devices for Migraine Therapy
Kusika kwezvigadziro kurapa nekudzivirira migraines kwakashandura migraine therapy. Izvi zvinowanzoita nyore nyore kushandisa, zviri nyore, uye zvakabatana nemigumisiro yakaipa. Izvozvo zvinodhura uye mari iyo zvimwe zvigadzirwa hazvibatsire munhu wose.
Kunyange zvakadaro, kuisa mari mune imwe chigamba kungave sarudzo yakakodzera kune vamwe vashandi, kunyanya kana mishonga isingashandisi, kana kune vanhu vanogona kutora mishonga inoderedza misoro .
Imwe migraine-kudzivirira chigonzi chinonzi Cefaly chinoshungurudza chirwere che supraorbital (tSNS) icho chisingabatanidzi chikamu chehuma, shisa uye maziso makuru. Icho chinhu chinoshandiswa nebheteri chakapfekedzwa sebhokisi rinoshandiswa zuva rega rega kwemaminitsi makumi maviri emaminitsi.
Iyo yakachengeteka, yakabvumirwa zvakanaka, uye yakashandiswa-user-friendly maererano nedzidzo huru mu Journal of Headache uye Pain, ine pasi pevashanu kubva muzana yevanhu vanotaura zviduku zvisingabatsiri. Icho chingave chakanaka chakanaka kune vanhu vasingakwanisi kutsungirira kana vasingadi kutora muromo migraine mishonga yekudzivirira.
Chimwe chigadzirwa ndechekusasvibisa vagus nerve stimulation (nVNS) device (inonzi GammaCore) iyo inogona kushandiswa kumativi maviri ekudzivirira uye kubata chirwere chakasimba chekudzivirira. Inoshanda kuburikidza nekusimudzira nhengo dzemawere-saka dzinobatwa nechepamusoro pemutsipa kwemaminitsi maviri mushure mekushandisa gel conductive. Zvinotendwa kushanda nekudzvinyirira huwandu hwemazinga e glutamate muhutatu hutsika.
Mune chidzidzo mu Journal of Headache uye Pain, zviitiko zvakaratidza kuvandudzwa kwehuwandu hwemusoro musoro pamwedzi, pamwe nekurwadziwa kwepamusoro, kune vatori vechikamu vane chirwere chepessed or chronic migraine disorder. Zvishomanana zvakashata zvinokonzerwa zvakasimbiswa uye hapana zvaive zvakakomba. Izvi zvinokonzerwa nemagumisiro zvaisanganisira kugunzva ganda uye mutsipa.
Chimwe chetatu chinonzi "Spring transcranial magnetic stimulator (sTMS)" "FDA-inogamuchirwa kuitira kurapa migraine neAra. Iyo inoshandiswa nekushandisa chigadziro kumusana wemusoro wako nekufambisa bhodhi, iyo inobudisa simba rinoita kuti magnetic energy muuropi. Inogona kushandiswa chete kamwe chete kwemaawa makumi mana nemasere sekurapa. Zvinotendwa kushanda nekudzvinyirirwa kortical kupararira kudengenyeka, ruzivo rwemagetsi anoshandura runopera muuropi.
Shoko Rinobva
Kunyange zvazvo mugumo wemishonga yemigraine nemishonga inofadza uye ichivimbisa, yeuka kuti kurapa nekudzivisa kubatwa kwako kwemasimba kunogona kuva kunetsa uye kusinganisa-kumwe kwekuedza uye kukanganisa kuchashandura sezvo migraines, mararamiro ako, uye / kana zvaunofarira zvinoshanduka.
Ramba uchishanda nesimba nekutevera neurologist yako nguva dzose uye uchiramba uchitarisana nemashoko e-migraine, usingatombogadzirwi zvakare pamagetsi ezvokurapa anobuda. Ngatitangei tarisiro kuti chirwere ichi chinoparadza chinogona kutakurwa zvishoma nokukurumidza kwauri kana mudiwa wako.
> Sources:
> Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Munguva pfupi yapfuura mushonga wemigraine. Springplus. 2016 May 17; 5: 637.
> Chan K, MaassenVanDenBrink A. Vanopikisa vanonzi Glutamate muhutungamiri hwemigraine. Zvinodhaka . 2014 Jul; 74 (11): 1165-76.
> Färkkilä M et al. Kubudirira uye kushivirira kwemasimiditan, yemuromo 5-HT (1F) receptor agonist, nokuda kwekurapa kwakanyanya kwemigraine: chikamu chechipiri randomized-placebo-controlled, parallel-group, study-doing-study. Lancet Neurol . 2012 May; 11 (5): 405-13.
> Magis D, Sava S, d / Elia TS, Baschi R, Schoenen J. Kuchengetedzwa uye kugutsikana kwevarwere zve transcutaneous supraorbital neurostimulation (tSNS) neCefaly device muhutano hwekurwadziwa: kuongororwa kwevanhu vanokwana 2 313 vane vhudzi vechirwere muhuwandu hwevanhu. J Headache Pain . 2013 Dec 1; 14: 95.
> Sun H et al. Kuchengetedzwa uye kubudirira kwe AMG 334 nekudzivirira kwechirwere chekudzivirira: epasidic, blind-blind, placebo-controlled, phase 2 muedzo. Lancet Neurol. 2016; 15 (4): 382-90.